Metastatic Bladder Cancer

J. L. Chin, K. M. Siddiqui, K. C. Tran

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Metastatic bladder cancer is one of the leading cause of genitourinary cancer-related morality. One-third of the patients are diagnosed with organ confined disease and 10-15% are estimated to present with metastasis. Five-year survival after radical surgery alone is 62-68%. One key limitation in management may be the inability of currently available imaging modalities to reliably detect occult metastases at the time of diagnosis. Choline positron emission tomography and multiparametric magnetic resonance imaging have shown promise in improving the detection of locally advanced disease. Several biomarkers such as p53 have been investigated and, although promising for prognostication and prediction for development of metastatic disease, they are still not recommended for routine use. Neoadjuvant chemotherapy has shown to reduce the risk of bladder cancer-related death by 33%, although treatment-related toxicity has to be taken into consideration. Newer agents such as TKI and PD-L1 inhibitors have shown promising results and are currently undergoing further trials.

Original languageEnglish
Title of host publicationIntroduction to Cancer Metastasis
PublisherElsevier Inc.
Pages177-198
Number of pages22
ISBN (Electronic)9780128040331
ISBN (Print)9780128040034
DOIs
Publication statusPublished - Dec 6 2016

Fingerprint

Urinary Bladder Neoplasms
Urogenital Neoplasms
Neoplasm Metastasis
Imaging techniques
Positron emission tomography
Chemotherapy
Biomarkers
Magnetic resonance
Choline
Positron-Emission Tomography
Surgery
Toxicity
Magnetic Resonance Imaging
Drug Therapy
Survival
Therapeutics

Keywords

  • Adjuvant chemotherapy
  • Biomarkers
  • Bladder cancer
  • Epidemiology of bladder cancer
  • Metastatic bladder cancer
  • Neoadjuvant chemotherapy
  • Palliation
  • Staging tools for bladder cancer

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Chin, J. L., Siddiqui, K. M., & Tran, K. C. (2016). Metastatic Bladder Cancer. In Introduction to Cancer Metastasis (pp. 177-198). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-804003-4.00010-4

Metastatic Bladder Cancer. / Chin, J. L.; Siddiqui, K. M.; Tran, K. C.

Introduction to Cancer Metastasis. Elsevier Inc., 2016. p. 177-198.

Research output: Chapter in Book/Report/Conference proceedingChapter

Chin, JL, Siddiqui, KM & Tran, KC 2016, Metastatic Bladder Cancer. in Introduction to Cancer Metastasis. Elsevier Inc., pp. 177-198. https://doi.org/10.1016/B978-0-12-804003-4.00010-4
Chin JL, Siddiqui KM, Tran KC. Metastatic Bladder Cancer. In Introduction to Cancer Metastasis. Elsevier Inc. 2016. p. 177-198 https://doi.org/10.1016/B978-0-12-804003-4.00010-4
Chin, J. L. ; Siddiqui, K. M. ; Tran, K. C. / Metastatic Bladder Cancer. Introduction to Cancer Metastasis. Elsevier Inc., 2016. pp. 177-198
@inbook{33799af9d71d410484f56116b41fea93,
title = "Metastatic Bladder Cancer",
abstract = "Metastatic bladder cancer is one of the leading cause of genitourinary cancer-related morality. One-third of the patients are diagnosed with organ confined disease and 10-15{\%} are estimated to present with metastasis. Five-year survival after radical surgery alone is 62-68{\%}. One key limitation in management may be the inability of currently available imaging modalities to reliably detect occult metastases at the time of diagnosis. Choline positron emission tomography and multiparametric magnetic resonance imaging have shown promise in improving the detection of locally advanced disease. Several biomarkers such as p53 have been investigated and, although promising for prognostication and prediction for development of metastatic disease, they are still not recommended for routine use. Neoadjuvant chemotherapy has shown to reduce the risk of bladder cancer-related death by 33{\%}, although treatment-related toxicity has to be taken into consideration. Newer agents such as TKI and PD-L1 inhibitors have shown promising results and are currently undergoing further trials.",
keywords = "Adjuvant chemotherapy, Biomarkers, Bladder cancer, Epidemiology of bladder cancer, Metastatic bladder cancer, Neoadjuvant chemotherapy, Palliation, Staging tools for bladder cancer",
author = "Chin, {J. L.} and Siddiqui, {K. M.} and Tran, {K. C.}",
year = "2016",
month = "12",
day = "6",
doi = "10.1016/B978-0-12-804003-4.00010-4",
language = "English",
isbn = "9780128040034",
pages = "177--198",
booktitle = "Introduction to Cancer Metastasis",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Metastatic Bladder Cancer

AU - Chin, J. L.

AU - Siddiqui, K. M.

AU - Tran, K. C.

PY - 2016/12/6

Y1 - 2016/12/6

N2 - Metastatic bladder cancer is one of the leading cause of genitourinary cancer-related morality. One-third of the patients are diagnosed with organ confined disease and 10-15% are estimated to present with metastasis. Five-year survival after radical surgery alone is 62-68%. One key limitation in management may be the inability of currently available imaging modalities to reliably detect occult metastases at the time of diagnosis. Choline positron emission tomography and multiparametric magnetic resonance imaging have shown promise in improving the detection of locally advanced disease. Several biomarkers such as p53 have been investigated and, although promising for prognostication and prediction for development of metastatic disease, they are still not recommended for routine use. Neoadjuvant chemotherapy has shown to reduce the risk of bladder cancer-related death by 33%, although treatment-related toxicity has to be taken into consideration. Newer agents such as TKI and PD-L1 inhibitors have shown promising results and are currently undergoing further trials.

AB - Metastatic bladder cancer is one of the leading cause of genitourinary cancer-related morality. One-third of the patients are diagnosed with organ confined disease and 10-15% are estimated to present with metastasis. Five-year survival after radical surgery alone is 62-68%. One key limitation in management may be the inability of currently available imaging modalities to reliably detect occult metastases at the time of diagnosis. Choline positron emission tomography and multiparametric magnetic resonance imaging have shown promise in improving the detection of locally advanced disease. Several biomarkers such as p53 have been investigated and, although promising for prognostication and prediction for development of metastatic disease, they are still not recommended for routine use. Neoadjuvant chemotherapy has shown to reduce the risk of bladder cancer-related death by 33%, although treatment-related toxicity has to be taken into consideration. Newer agents such as TKI and PD-L1 inhibitors have shown promising results and are currently undergoing further trials.

KW - Adjuvant chemotherapy

KW - Biomarkers

KW - Bladder cancer

KW - Epidemiology of bladder cancer

KW - Metastatic bladder cancer

KW - Neoadjuvant chemotherapy

KW - Palliation

KW - Staging tools for bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=85021933683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021933683&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-804003-4.00010-4

DO - 10.1016/B978-0-12-804003-4.00010-4

M3 - Chapter

SN - 9780128040034

SP - 177

EP - 198

BT - Introduction to Cancer Metastasis

PB - Elsevier Inc.

ER -